Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly EPS; no daily interpolation.
Limited quarterly history available
EPS needs at least three reported quarters before a meaningful chart is shown.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
N/A
EARNINGS PER SHARE (EPS) AVG 3Y
N/A
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.44B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Earnings Per Share (EPS)
N/A
TTM Avg
-1.26
3Y Avg
-1.26
5Y Avg
-1.26
Market Cap
$1.45B
Earnings Per Share (EPS)
5.37
TTM Avg
-2.79
3Y Avg
-4.06
5Y Avg
-3.18
Market Cap
$1.47B
Earnings Per Share (EPS)
1.71
TTM Avg
0.68
3Y Avg
0.58
5Y Avg
0.72
Market Cap
$1.40B
Earnings Per Share (EPS)
-8.88
TTM Avg
53.77
3Y Avg
24.70
5Y Avg
19.33
Market Cap
$1.36B
Earnings Per Share (EPS)
N/A
TTM Avg
-3.20
3Y Avg
-3.20
5Y Avg
-3.20
Market Cap
$1.52B
Earnings Per Share (EPS)
-1.00
TTM Avg
-0.77
3Y Avg
-0.59
5Y Avg
-0.43
Market Cap
$1.35B
Earnings Per Share (EPS)
-1.04
TTM Avg
-0.49
3Y Avg
-0.48
5Y Avg
-0.41
Market Cap
$1.53B
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.44B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | -1.26 | -1.26 | -1.26 |
| AnaptysBio, Inc. (ANAB)vs › | $1.45B | 5.37 | -2.79 | -4.06 | -3.18 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 1.71 | 0.68 | 0.58 | 0.72 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -8.88 | 53.77 | 24.70 | 19.33 |
| Kardigan, Inc. (KARD)vs › | $1.36B | N/A | -3.20 | -3.20 | -3.20 |
| GH Research PLC (GHRS)vs › | $1.52B | -1.00 | -0.77 | -0.59 | -0.43 |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.35B | -1.04 | -0.49 | -0.48 | -0.41 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.53B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.53B | 0.38 | -0.16 | -0.18 | -0.35 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
$-3.10
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.33 |
